[go: up one dir, main page]

UY27039A1 - Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción - Google Patents

Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción

Info

Publication number
UY27039A1
UY27039A1 UY27039A UY27039A UY27039A1 UY 27039 A1 UY27039 A1 UY 27039A1 UY 27039 A UY27039 A UY 27039A UY 27039 A UY27039 A UY 27039A UY 27039 A1 UY27039 A1 UY 27039A1
Authority
UY
Uruguay
Prior art keywords
forms
ureido
bromo
ilbutil
isotiazol
Prior art date
Application number
UY27039A
Other languages
English (en)
Inventor
Thomas G Gant
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27039A1 publication Critical patent/UY27039A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a las formas de sal hidrocloruro, hidrobromuro, hemicitrato, acetato, p-tosilato, L-tartrato, hemisuccinato y mesilato de amida de ácido 3-(4-bromo-2,6-difluorobenciloxi)-5-(3-(4-pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico que tiene la fórmula (I); la invención también se refiere a composiciones farmaceuticas que contienen las sales hidrocloruro, hemicitrato, acetato. P-tosilato, hemisuccinato y mesilato de formula (I). La invención se refiere además a métodos para tratar enfermedades hiperproliferativas, tales como cánceres en mamíferos, especialmente seres humanos, por administración de las sales anteriores, y a los métodos para preparar las formas cristalinas de las sales anteriores.
UY27039A 2000-11-28 2001-11-26 Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción UY27039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28

Publications (1)

Publication Number Publication Date
UY27039A1 true UY27039A1 (es) 2002-07-31

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27039A UY27039A1 (es) 2000-11-28 2001-11-26 Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción

Country Status (49)

Country Link
US (1) US6831091B2 (es)
EP (1) EP1337521B1 (es)
JP (2) JP2004514714A (es)
KR (2) KR20050116401A (es)
CN (1) CN1231474C (es)
AP (1) AP2001002358A0 (es)
AR (1) AR031512A1 (es)
AT (1) ATE340786T1 (es)
AU (2) AU2002214204B2 (es)
BG (1) BG107752A (es)
BR (1) BR0115621A (es)
CA (1) CA2430065C (es)
CR (1) CR6963A (es)
CY (1) CY1106240T1 (es)
CZ (1) CZ20031315A3 (es)
DE (1) DE60123461T2 (es)
DK (1) DK1337521T3 (es)
DO (1) DOP2001000288A (es)
EA (1) EA005859B1 (es)
EC (1) ECSP034628A (es)
EE (1) EE200300247A (es)
ES (1) ES2271086T3 (es)
GE (1) GEP20053652B (es)
GT (1) GT200100237A (es)
HN (1) HN2001000268A (es)
HR (1) HRP20030408A2 (es)
HU (1) HUP0302553A3 (es)
IL (1) IL155371A0 (es)
IS (1) IS6788A (es)
MA (1) MA26960A1 (es)
MX (1) MXPA03004714A (es)
MY (1) MY136686A (es)
NO (1) NO325187B1 (es)
NZ (1) NZ525788A (es)
OA (1) OA12532A (es)
PA (1) PA8533801A1 (es)
PE (1) PE20020591A1 (es)
PL (1) PL362079A1 (es)
PT (1) PT1337521E (es)
SI (1) SI1337521T1 (es)
SK (1) SK5862003A3 (es)
SV (1) SV2002000748A (es)
TN (1) TNSN01167A1 (es)
TW (1) TWI287542B (es)
UA (1) UA74221C2 (es)
UY (1) UY27039A1 (es)
WO (1) WO2002044158A1 (es)
YU (1) YU36403A (es)
ZA (1) ZA200303341B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003281664A1 (en) * 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
PL375713A1 (en) * 2002-08-19 2005-12-12 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
BRPI0415836A (pt) * 2003-10-27 2007-01-02 Merck & Co Inc composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8722684B2 (en) 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
US20130177500A1 (en) 2010-07-23 2013-07-11 Trustee Of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
CN105142686B (zh) * 2013-03-14 2020-04-10 帕恩欧普佳有限公司 给药于眼后段的眼用制剂
US9814702B2 (en) * 2014-09-17 2017-11-14 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
WO2024140850A1 (zh) * 2022-12-28 2024-07-04 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
PE20020591A1 (es) 2002-07-06
BG107752A (bg) 2004-01-30
EP1337521B1 (en) 2006-09-27
AP2001002358A0 (en) 2001-12-31
IL155371A0 (en) 2003-11-23
GEP20053652B (en) 2005-11-10
US20020151573A1 (en) 2002-10-17
PL362079A1 (en) 2004-10-18
CZ20031315A3 (cs) 2004-04-14
EA005859B1 (ru) 2005-06-30
KR20050116401A (ko) 2005-12-12
SI1337521T1 (sl) 2006-12-31
CA2430065A1 (en) 2002-06-06
CR6963A (es) 2003-11-25
EE200300247A (et) 2003-10-15
TNSN01167A1 (fr) 2005-11-10
NO20032388L (no) 2003-07-18
MXPA03004714A (es) 2003-08-19
TWI287542B (en) 2007-10-01
MY136686A (en) 2008-11-28
HN2001000268A (es) 2002-01-30
US6831091B2 (en) 2004-12-14
NO325187B1 (no) 2008-02-11
HRP20030408A2 (en) 2003-08-31
EP1337521A1 (en) 2003-08-27
NO20032388D0 (no) 2003-05-27
ATE340786T1 (de) 2006-10-15
JP2004514714A (ja) 2004-05-20
SK5862003A3 (en) 2004-05-04
PT1337521E (pt) 2006-12-29
OA12532A (en) 2006-06-02
DOP2001000288A (es) 2002-12-15
KR20030059275A (ko) 2003-07-07
CN1231474C (zh) 2005-12-14
AR031512A1 (es) 2003-09-24
DE60123461D1 (de) 2006-11-09
UA74221C2 (uk) 2005-11-15
WO2002044158A1 (en) 2002-06-06
ECSP034628A (es) 2003-07-25
ZA200303341B (en) 2004-04-30
HK1059085A1 (en) 2004-06-18
ES2271086T3 (es) 2007-04-16
DE60123461T2 (de) 2007-02-15
IS6788A (is) 2003-04-14
AU1420402A (en) 2002-06-11
CY1106240T1 (el) 2011-06-08
AU2002214204B2 (en) 2007-05-24
YU36403A (sh) 2006-08-17
MA26960A1 (fr) 2004-12-20
JP4971946B2 (ja) 2012-07-11
JP2008056692A (ja) 2008-03-13
HUP0302553A2 (hu) 2003-11-28
GT200100237A (es) 2002-07-03
BR0115621A (pt) 2003-09-02
CN1476439A (zh) 2004-02-18
NZ525788A (en) 2004-11-26
EA200300424A1 (ru) 2003-10-30
DK1337521T3 (da) 2007-01-29
HUP0302553A3 (en) 2009-03-30
CA2430065C (en) 2008-05-20
SV2002000748A (es) 2002-12-02
PA8533801A1 (es) 2002-10-31

Similar Documents

Publication Publication Date Title
UY27039A1 (es) Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
AR032679A1 (es) Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz
UY26872A1 (es) Derivados de la 4- fenil piridina
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
UY28374A1 (es) Agentes terapéuticos
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
BRPI0507786A (pt) composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
UY27593A1 (es) Nuevos compuestos
AR044830A1 (es) Derivados de 4,5 diaril -3-heterociclilpirazin- 2- ester
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
BR0315839A (pt) Derivados de prolina tendo afinidade para a subunidade alfa-2-delta do canal de cálcio
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
BRPI0811245A2 (pt) Composto de carbamoilóxi-aril-alcanoil-aril-piperazinas, composições farmacêuticas que compreendem o composto, e método para tratar dor, ansiedade e depressão administrando o composto.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
CO5570673A2 (es) Compuestos azapoliciclicos condensados con arilo
BR0015877A (pt) Polimorfo v de torasemida
MX2009010729A (es) Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.
EA200700807A1 (ru) Новые циклические и ациклические пропеноны для лечения заболеваний цнс

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141107